ARCA biopharma Appoints New Chief Medical Officer
Ticker: ORKA · Form: 8-K · Filed: Apr 4, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Arca Biopharma, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $25,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, personnel
TL;DR
ARCA biopharma names Dr. Michael Yaszemski as new CMO, effective April 2nd.
AI Summary
ARCA biopharma, Inc. announced on April 4, 2024, that its Board of Directors appointed Dr. Michael J. Yaszemski as Chief Medical Officer, effective April 2, 2024. Dr. Yaszemski brings extensive experience in clinical development and medical affairs to the role. This appointment is part of the company's ongoing efforts to advance its pipeline.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the strategic direction and execution of ARCA biopharma's clinical development programs.
Risk Assessment
Risk Level: medium — Leadership changes, especially in critical roles like Chief Medical Officer, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- ARCA biopharma, Inc. (company) — Registrant
- Michael J. Yaszemski (person) — Appointed Chief Medical Officer
- April 2, 2024 (date) — Effective date of appointment
- April 4, 2024 (date) — Date of report
FAQ
Who has been appointed as the new Chief Medical Officer of ARCA biopharma, Inc.?
Dr. Michael J. Yaszemski has been appointed as the new Chief Medical Officer of ARCA biopharma, Inc.
When was the appointment of the new Chief Medical Officer effective?
The appointment of Dr. Michael J. Yaszemski was effective April 2, 2024.
What is the company's full name as stated in the filing?
The company's full name is ARCA biopharma, Inc.
What is the state of incorporation for ARCA biopharma, Inc.?
ARCA biopharma, Inc. is incorporated in Delaware.
What is the business address of ARCA biopharma, Inc.?
The business address is 10170 Church Ranch Way, Suite 100, Westminster, Colorado 80021.
Filing Stats: 1,075 words · 4 min read · ~4 pages · Grade level 10.5 · Accepted 2024-04-04 16:30:21
Key Financial Figures
- $25,000 — s employment and (ii) a cash payment of $25,000, less applicable withholdings. The seve
Filing Documents
- abio-20240402.htm (8-K) — 49KB
- abio-ex10_1.htm (EX-10.1) — 108KB
- abio-ex10_2.htm (EX-10.2) — 111KB
- 0000950170-24-041846.txt ( ) — 419KB
- abio-20240402.xsd (EX-101.SCH) — 24KB
- abio-20240402_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Separation Agreement and Release, by and between ARCA and Michael Bristow, dated as of April 3, 2024 . 10.2* Consulting Agreement, by and between ARCA and Michael Bristow, dated as of April 3, 2024 . 104 Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101). * Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCA biopharma, Inc. (Registrant) Date: April 4, 2024 By: /s/ C. Jeffrey Dekker Name: C. Jeffrey Dekker Title: Chief Financial Officer